Table 2. ORs of the clinical, muscle, adiposity and bioelectrical data for low muscle mass1 and obesity2 risk.
| Low Muscle Mass1 | ||||
|---|---|---|---|---|
| Sex | OR (95%CI) | Sex | OR (95%CI) | |
| Age (years) | Female | 0.99 (0.95, 1.02) | Male | 1.00 (0.97, 1.04) |
| Chronic kidney disease treatment group3 | Female | 1.38 (0.99, 1.91) | Male | 1.26 (0.95, 1.65) |
| Dialysis or kidney transplant time (month) | Female | 1.00 (0.99, 1.01) | Male | 1.00 (0.99, 1.00) |
| Estimated glomerular filtration rate (ml/min/1.73m2) | Female | 1.02 (1.00, 1.04) | Male | 1.02 (1.00, 1.03) |
| KT/V | Female | 1.25 (0.49, 3.17) | Male | 1.00 (0.29, 3.35) |
| Diabetes Mellitus4 | Female | 0.74 (0.33, 1.66) | Male | 0.60 (0.50, 1.40) |
| Weight (kg) | Female | 0.81 (0.76, 0.87)* | Male | 0.85 (0.81, 0.90)* |
| Body mass index (kg/m2) | Female | 0.73 (0.65, 0.82)* | Male | 0.72 (0.64, 0.81)* |
| Lean mass (kg) by dual energy X-ray absorptiometry analysis | Female | 0.44 (0.33, 0.60)* | Male | 0.53 (0.42, 0.66)* |
| Fat mass (kg) by dual energy X-ray absorptiometry analysis | Female | 0.85 (0.80, 0.90)* | Male | 0.90 (0.85, 0.94)* |
| Hand grip strength (kg) | Female | 0.87 (0.81, 0.94)* | Male | 0.92 (0.87, 0.96)* |
| Mid arm muscle circumference (cm) | Female | 0.67 (0.56, 0.80)* | Male | 0.70 (0.59, 0.83)* |
| Arm muscle area (cm2) | Female | 0.90 (0.86, 0.94)* | Male | 0.91 (0.90, 0.95)* |
| Corrected arm muscle area (cm2) | Female | 0.90 (0.86, 0.94)* | Male | 0.91 (0.88, 0.95)* |
| Adductor pollicis muscle thickness (mm) | Female | 0.83 (0.75, 0.92)* | Male | 0.76 (0.68, 0.85)* |
| Calf circumference (cm) | Female | 0.54 (0.43, 0.67)* | Male | 0.61 (0.51, 0.73)* |
| Phase angle (°) | Female | 0.65 (0.43, 0.98)* | Male | 0.87 (0.59, 1.30) |
| Body cell mass (kg) | Female | 0.70 (0.61, 0.81)* | Male | 0.80 (0.73, 0.88)* |
| Body cell mass index (kg/m2) | Female | 0.53 (0.39, 0.72)* | Male | 0.70 (0.56, 0.98)* |
| Fat free mass body composition monitor (kg) | Female | 0.77 (0.70, 0.86)* | Male | 0.85 (0.79, 0.91)* |
| Fat free mass body composition monitor (%) | Female | 1.05 (1.01, 1.08)* | Male | 1.05 (1.01, 1.07)* |
| Fat free mass index body composition monitor (kg/m2) | Female | 0.62 (0.49, 0.78)* | Male | 0.76 (0.65, 0.90)* |
| Predicted fat free mass (kg) | Female | 0.43 (0.32, 0.59)* | Male | 0.64 (0.55, 0.76)* |
| Predicted fat free mass (%) | Female | 1.20 (1.10, 1.31)* | Male | 1.03 (0.97, 1.09) |
| Predicted fat free mass index (kg/m2) | Female | 0.43 (0.31, 0.58)* | Male | 0.46 (0.34, 0.61)* |
| Appendicular fat free mass (kg) | Female | 0.18 (0.10, 0.34)* | Male | 0.32 (0.22, 0.48)* |
| Obesity2 | ||||
| Age (years) | Female | 1.11 (1.03, 1.20)* | Male | 1.03 (0.99, 1.07) |
| Chronic kidney disease treatment group3 | Female | 0.78 (0.52, 1.20) | Male | 0.89 (0.66, 1.20) |
| Dialysis or kidney transplant time (month) | Female | 1.00 (0.99, 1.01) | Male | 1.00 (0.99, 1.01) |
| Estimated glomerular filtration rate (ml/min/1.73m2) | Female | 0.99 (0.97, 1.01) | Male | 0.99 (0.97, 1.01) |
| KT/V | Female | 0.41 (0.72, 2.44) | Male | 0.98 (0.20, 4.81) |
| Diabetes mellitus4 | Female | 4.41 (1.71, 11.38)* | Male | 2.49 (1.13, 5.48)* |
| Weight (kg) | Female | 1.15 (1.08, 1.21)* | Male | 1.14 (1.09, 1.20)* |
| Body mass index (kg/m2) | Female | 2.05 (1.50, 2.78)* | Male | 2.32 (1.70, 3.16)* |
| Hand grip strength (kg) | Female | 0.92 (0.84, 1.01) | Male | 0.98 (0.94, 1.02) |
| Phase angle (°) by bioelectrical impedance analysis | Female | 0.95 (0.59, 1.54) | Male | 1.03 (0.68, 1.53) |
| Body cell mass (kg) by bioelectrical impedance analysis | Female | 0.90 (0.80, 1.02) | Male | 0.98 (0.91, 1.05) |
| Mid arm circumference (cm) | Female | 1.60 (1.32, 1.94)* | Male | 1.77 (1.45, 2.15)* |
| Waist circumference (cm) | Female | 1.23 (1.13, 1.33)* | Male | 1.30 (1.18, 1.44)* |
| Waist circumference/Height | Female | 8.87 (2.24, 3.51)* | Male | 2.17 (1.68, 2.80)* |
| Triceps skin fold thickness (mm) | Female | 1.18 (1.11, 1.25)* | Male | 1.40 (1.24, 1.57)* |
| Fat mass body composition monitor (kg) | Female | 1.59 (1.29, 1.96)* | Male | 1.36 (1.22, 1.51)* |
| Fat mass body composition monitor (%) | Female | 1.50 (1.27, 1.76)* | Male | 1.35 (1.21, 1.51)* |
| Fat mass index body composition monitor (kg/m2) | Female | 4.58 (2.13, 9.86)* | Male | 3.15 (2.10, 4.78)* |
| Predicted fat mass (kg) | Female | 1.51 (1.27, 1.78)* | Male | 1.56 (1.32, 1.83)* |
| Predicted fat mass (%) | Female | 2.37 (1.64, 3.41)* | Male | 1.73 (1.43, 2.10)* |
| Predicted fat mass index (kg/m2) | Female | 6.43 (2.41, 17.11)* | Male | 5.48 (2.86, 10.52)* |
1ALM with dual energy X-ray absorptiometry measurement, for women, ALM<15kg, for men, ALM<20kg [10].
2FMI with dual energy X-ray absorptiometry measurement, for women, FMI>13kg/m2, for men, FMI>9kg/m2 [14].
3NDD CKD group as reference.
4Presence of diagnostic of Diabetes Mellitus as reference.
*p≤0.05. Phase angle, body cell mass, body cell mass index, fat free mass body composition monitor, fat free mass index body composition monitor, predicted fat free mass, predicted fat free mass index, appendicular fat free mass, fat mass body composition monitor, fat mass index body composition monitor, predicted fat mass and predicted fat mass index, by bioelectrical impedance. Appendicular fat free mass by Sergi equation [20]; predicted fat free mass and predicted fat mass by Bellafronte equation [22]; Fat free mass body composition monitor and fat mass body composition monitor by bioelectrical impedance from body composition monitor (Fresenius Medical Care).